Overview

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess Pharmakokinetic properties of iron isomaltoside 1000 (Monofer®) in doses of 250 mg and 500 mg in patients suffering from Chemotherapy Induced anemia.

Phase:

Phase 1

Details

Lead Sponsor:

Pharmacosmos A/S

Treatments:

Ferric Compounds
Iron isomaltoside 1000